Last reviewed · How we verify
NCT06224283: Cryomics
Radiomics Compared With Conventional Response Criteria for Predicting Progression of Desmoid Tumor After Cryoablation
trial testing Cryoablation in Desmoid in 21 participants. Currently enrolling.
31 October 2026
Quick facts
| Lead sponsor | Istituto Ortopedico Rizzoli |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 21 |
| Start date | 20 February 2024 |
| Primary completion | 31 October 2026 |
| Estimated completion | 31 October 2026 |
| Sites | 1 location across Italy |
Drugs / interventions tested
- Cryoablation — full drug profile →
Conditions studied
- Desmoid — all drugs for Desmoid →
Sponsor
Istituto Ortopedico Rizzoli — full company profile →
Who can join
Eligibility, any sex, with Desmoid. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Desmoid tumors (DT) are uncommon tumors that arise from musculoaponeurotic structures. Despite benign, they can cause pain and disability due to their tendency to be locally aggressive. Cryoablation, a technique used in interventional radiology, has gained popularity in recent years as a treatment option for sporadic DT. This involves repeated cycles of freezing, leading to cell death. Recent studies showed that percutaneous image-guided cryoablation appears to be safe and effective for local control for patients with extra-abdominal desmoid tumors.Although changes in the heterogeneity of tumors are commonly known, they are often ignored in response criteria that only evaluate tumor size in a single dimension, such as Response Evaluation Criteria in Solid Tumors (RECIST 1.1). Nevertheless, MRI can reveal early changes in tumor heterogeneity in responding tumors, resulting from a reduction in cellular area and an increase in fibro-necrotic content, before any dimensional changes occur. These changes in heterogeneity can be quantified using a radiomics approach. The aim of this study is to develop radiomics response criteria dedicated to the evaluation of DT treated with cryoablation as a first line treatment and to compare their performance with those of alternative radiologic response criteria for predicting progression according to RECIST 1.1.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06224283
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Cryoablation
Trials testing the same drug.
- NCT07380789 — Comprehensive Multicenter Study on the Management of Acute Pain Following Thoracic Combat-Related Trauma in Ukraine · NA · recruiting
- NCT07306286 — Cryoablation Combined With the Dual-Function Antibody PD-1/CTLA-4 for the Treatment of LAPC Following Failure of First-L · Phase 2 · recruiting
- NCT07147088 — Cryoablation Combined With SHR-1701 Plus Famitinib in Patients With Advanced Intrahepatic Cholangiocarcinoma. · Phase 2 · not yet recruiting
- NCT06991231 — The Benefits Of Cryoablation In Patients Undergoing Total Knee Arthroplasty · NA · recruiting
- NCT06848881 — Cryoablation vs Thoracoscopic Surgery for GGN · NA · recruiting
Other recruiting trials for Desmoid
Currently open trials in the same condition.
- NCT06502483 — PRISM for Depression and Anxiety in Young Adults With Cancer · NA · active not recruiting
- NCT06268457 — Arterial Chemoembolization for the Treatment of Desmoid Fibromatosis · recruiting
- NCT05919264 — FOG-001 in Locally Advanced or Metastatic Solid Tumors · Phase 1, PHASE2 · recruiting
- NCT05091255 — Cryotherapy in the Treatment of Desmoid Tumors · NA · recruiting
Other Istituto Ortopedico Rizzoli trials
Trials by the same sponsor.
- NCT07590882 — Evaluation of Return to Sports Activity After Periacetabular Osteotomy: An Observational Study · enrolling by invitation
- NCT07021222 — Multifactorial Strategies for the Prevention of the Risks of Ulceration in Patients Affected by Diabetic Foot (DARE-DiaF · NA · recruiting
- NCT07360964 — Clear Cell Chondrosarcoma in Italy · NA · active not recruiting
- NCT07140367 — "Transarterial Microembolization (TAME) in Inflammatory Knee Pathology" · recruiting
- NCT07102875 — Ready to Sail 2: A Pilot Study of Sail-Assisted Telerehabilitation in Rare Skeletal Diseases · NA · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06224283 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Istituto Ortopedico Rizzoli
- Last refreshed: 24 January 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06224283.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing